Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014

References

• Ali, M. M., J. L. Teich, and R. Mutter. 2015. The role of perceived need and health insurance in substance use treatment: Implications for the Affordable Care Act. Journal of Substance Abuse Treatment 54:14–20. doi:10.1016/j.jsat.2015.02.002.
   PubMed Web of Science ®Google Scholar
• American Society of Addiction Medicine. 2015. National practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD: American Society of Addiction Medicine. http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf?sfvrsn=24
   Google Scholar
• Beronio, K., S. Glied, and R. Frank. 2014. How the Affordable Care Act and Mental Health Parity and Addiction Equity Act greatly expand coverage of behavioral health care. The Journal of Behavioral Health Services & Research 41 (4):410–28. doi:10.1007/s11414-014-9412-0.
   PubMed Web of Science ®Google Scholar
• Busch, S. H., A. J. Epstein, M. O. Harhay, D. A. Fiellin, H. Un, D. Leader Jr., and C. L. Barry. 2014. The effects of federal parity on substance use disorder treatment. The American Journal of Managed Care 20 (1):76–82.
   PubMed Web of Science ®Google Scholar
• CDC. 2016. Injury prevention & control: Opioid overdose. Atlanta, GA: Centers for Disease Control and Prevention.
   Google Scholar
• Creedon, T. B., and B. L. Cook. 2016. Access to mental health care increased but not for substance use, while disparities remain. Health Affairs 35 (6):1017–21. doi:10.1377/hlthaff.2016.0098.
   PubMed Web of Science ®Google Scholar
• Dick, A. W., R. L. Pacula, A. J. Gordon, M. Sorbero, R. M. Burns, D. Leslie, and B. D. Stein. 2015. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Affairs 34 (6):1028–34. doi:10.1377/hlthaff.2014.1205.
   PubMed Web of Science ®Google Scholar
• Ettner, S. L., J. M. Harwood, A. Thalmayer, M. K. Ong, H. Xu, M. J. Bresolin, K. B. Wells, C. H. Tseng, and F. Azocar. 2016. The Mental Health Parity and Addiction Equity Act evaluation study: Impact on specialty behavioral health utilization and expenditures among “carve-out” enrollees. Journal of Health Economics 50:131–43. doi:10.1016/j.jhealeco.2016.09.009.
   PubMed Web of Science ®Google Scholar
• Fullerton, C. A., M. Kim, C. P. Thomas, D. R. Lyman, L. B. Montejano, R. H. Dougherty, A. S. Daniels, S. S. Ghose, and M. E. Delphin-Rittmon. 2014. Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services 65 (2):146–57. doi:10.1176/appi.ps.201300235.
   PubMed Web of Science ®Google Scholar
• Gastfriend, D. R. 2011. Intramuscular extended-release naltrexone: Current evidence. Annals of the New York Academy of Sciences 1216:144–66. doi:10.1111/nyas.2011.1216.issue-1.
   PubMed Web of Science ®Google Scholar
• Horgan, C. M., D. Hodgkin, M. T. Stewart, A. Quinn, E. L. Merrick, S. Reif, D. W. Garnick, and T. B. Creedon. 2016a. Health plans’ early response to federal parity legislation for mental health and addiction services. Psychiatric Services 67 (2):162–68. doi:10.1176/appi.ps.201400575.
   PubMed Web of Science ®Google Scholar
• Horgan, C. M., M. T. Stewart, S. Reif, D. W. Garnick, D. Hodgkin, E. L. Merrick, and A. E. Quinn. 2016b. Behavioral health services in the changing landscape of private health plans. Psychiatric Services 67 (6):622–29. doi:10.1176/appi.ps.201500235.
   PubMed Web of Science ®Google Scholar
• Jones, C. M., M. Campopiano, G. Baldwin, and E. McCance-Katz. 2015. National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health 105 (8):e55–63. doi:10.2105/AJPH.2015.302664.
   PubMed Web of Science ®Google Scholar
• Kanouse, A. B., and P. Compton. 2015. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. Journal of Pain & Palliative Care Pharmacotherapy 29 (2):102–14. doi:10.3109/15360288.2015.1037521.
   PubMedGoogle Scholar
• Kasarabada, N. D., Y. I. Hser, S. M. Boles, and Y. C. Huang. 2002. Do patients’ perceptions of their counselors influence outcomes of drug treatment? Journal of Substance Abuse Treatment 23 (4):327–34. doi:10.1016/S0740-5472(02)00276-3.
   PubMed Web of Science ®Google Scholar
• Kemper, P., D. Blumenthal, J. M. Corrigan, P. J. Cunningham, S. M. Felt, J. M. Grossman, L. T. Kohn, C. E. Metcalf, R. F. Peter St., R. C. Strouse, and P. B. Ginsburg. 1996. The design of the community tracking study: A longitudinal study of health system change and its effects on people. Inquiry 33 (2):195–206.
   PubMed Web of Science ®Google Scholar
• Knopf, A. 2016, October. Methadone remains vital in buprenorphine era. Addiction Professional Magazine.
   Google Scholar
• Knudsen, H. K. 2015. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: A state-level analysis. Journal of Studies on Alcohol and Drugs 76 (4):644–54. doi:10.15288/jsad.2015.76.644.
   PubMed Web of Science ®Google Scholar
• Mark, T. L., T. Yee, K. R. Levit, J. Camacho-Cook, E. Cutler, and C. D. Carroll. 2016. Insurance financing increased for mental health conditions but not for substance use disorders, 1986–2014. Health Affairs 35 (6):958–65. doi:10.1377/hlthaff.2016.0002.
   Web of Science ®Google Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (Online) (2):CD002207.
   PubMed Web of Science ®Google Scholar
• Oliva, E. M., N. C. Maisel, A. J. Gordon, and A. H. Harris. 2011. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports 13 (5):374–81. doi:10.1007/s11920-011-0222-2.
   PubMed Web of Science ®Google Scholar
• ONDCP, 2016. The epidemic of prescription drug and heroin abuse in the United States. Committee on Oversight and Government Reform United States House of Representatives. https://oversight.house.gov/wp-content/uploads/2016/03/Botticelli-ONDCP-Statement-3-22-Heroin-Opioid-Abuse.pdf.
   Google Scholar
• Reif, S., C. M. Horgan, D. Hodgkin, A. M. Matteucci, T. B. Creedon, and M. T. Stewart. 2016. Access to addiction pharmacotherapy in private health plans. Journal of Substance Abuse Treatment 66:23–29. doi:10.1016/j.jsat.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Rudd, R. A., N. Aleshire, J. E. Zibbell, and R. Matthew Gladden. 2016. Increases in drug and opioid overdose deaths—United States, 2000–2014. American Journal of Transplantation 16 (4):1323–27. doi:10.1111/ajt.13776.
   Web of Science ®Google Scholar
• Saloner, B., S. N. Bandara, E. E. McGinty, and C. L. Barry. 2016. Justice-involved adults with substance use disorders: Coverage increased but rates of treatment did not in 2014. Health Affairs 35 (6):1058–66. doi:10.1377/hlthaff.2016.0005.
   Web of Science ®Google Scholar
• SAMHSA. 2013. Drug Abuse Warning Network, 2011: National estimates of drug-related emergency department visits. HHS publication no. (SMA) 13-4760, DAWN series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration.
   Google Scholar
• SAMHSA. 2015a. Federal guidelines for opioid treatment programs. Rockville, MD: HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration.
   Google Scholar
• SAMHSA. 2015b. National Survey of Substance Abuse Treatment Services (N-SSATS) 2014: Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration.
   Google Scholar
• SAMHSA. 2016. Results from the 2015 national survey on drug use and health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Schackman, B. R., J. A. Leff, D. Polsky, B. A. Moore, and D. A. Fiellin. 2012. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Journal of General Internal Medicine 27 (6):669–76. doi:10.1007/s11606-011-1962-8.
   PubMed Web of Science ®Google Scholar
• Stein, B. D., A. J. Gordon, A. W. Dick, R. M. Burns, R. L. Pacula, C. M. Farmer, D. L. Leslie, and M. Sorbero. 2015. Supply of buprenorphine waivered physicians: The influence of state policies. Journal of Substance Abuse Treatment 48 (1):104–11. doi:10.1016/j.jsat.2014.07.010.
   PubMed Web of Science ®Google Scholar
• Tamburro, L. P., J. H. Al-Hadidi, and L. J. Dragovic. 2016. Resurgence of fentanyl as a drug of abuse. Journal Forensic Sciences Medica 2:111–14. doi:10.4103/2349-5014.184195.
   Google Scholar
• Thalmayer, A. G., S. A. Friedman, F. Azocar, J. M. Harwood, and S. L. Ettner. 2016. The Mental Health Parity and Addiction Equity Act (MHPAEA) evaluation study: Impact on quantitative treatment limits. Psychiatric Services, Advance Online Publication. doi:10.1176/appi.ps.201600110.
   PubMed Web of Science ®Google Scholar
• Thomas, C. P., C. A. Fullerton, M. Kim, L. Montejano, D. R. Lyman, R. H. Dougherty, A. S. Daniels, S. S. Ghose, and M. E. Delphin-Rittmon. 2014. Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services 65 (2):158–70. doi:10.1176/appi.ps.201300256.
   PubMed Web of Science ®Google Scholar
• U.S. DHHS. 2016. The opioid epidemic: By the numbers. Washington, DC: U.S. Department of Health and Human Services.
   Google Scholar
• U.S. Surgeon General. 2016. Turn the tide: The Surgeon General’s call to end the opioid crisis. Washington, DC: U.S. Department of Health and Human Services.
   Google Scholar
• Volkow, N. D., T. R. Frieden, P. S. Hyde, and S. S. Cha. 2014. Medication-assisted therapies—tackling the opioid-overdose epidemic. The New England Journal of Medicine 370 (22):2063–66. doi:10.1056/NEJMp1402780.
   PubMed Web of Science ®Google Scholar